It is now 1 year and 8 months since Molecular Oncology became fully Open Access in 2017 under the FEBS Press platform and Wiley. Interestingly, the number of submissions remained comparable during 2016 and 2017, and we are delighted to report that so far in 2018, submissions have almost doubled as compared to the same period last year.
To tackle the increase in submissions, we recently appointed Section Editors in basic/preclinical research (Michael Boutros, Heidelberg, Germany; George Ca lin, Houston, USA; Gerry Melino, Cambridge, UK) and in clinical research (Mef Nilbert, Copenhagen, Denmark; Klaus Pantel, Hamburg, Germany) . Their expertise and commitment will be essential to the future development of the Journal, and together with the Editor-in-Chief, they will apply the same rigorous standards of peer review to ensure that the journal keeps its high standing among cancer journals worldwide.
In addition, we have strengthened the Editorial office by appointing Duncan Wright as Editorial Associate to coordinate editorial matters. Moreover, we have put into operation significant changes to the Web site to facilitate access to critical information.
I want to take this opportunity to thank Jos e Moreira, with whom I started the Journal in 2007, for his instrumental and countless contributions to the development of the Journal, in particular during the more difficult early years. Jos e will remain at the Journal as Review Editor. I would also like to thank Dorte Holst Pedersen, our Editorial Assistant, for her valuable support, and Mary Purton, Coordinator of FEBS Press, for her continuous advice during the transition process.
Finally, I would like to convey my sincere thanks to the readers for their continuing support and take this opportunity to invite you to submit your research articles to Molecular Oncology. , focuses upon programmed cell death in epidermal and neural models, and in particular on the family members of the tumor suppressor p53, namely p73 and p63. He identified splicing isoforms of p73 and p63, their involvement in DNA damage response, transcriptional regulation, degradation pathways, and mechanisms of death. His group has developed knockout mouse models to understand the biology of both p73 and p63. He previously worked on transglutaminases' role in the formation of the cornified envelope in skin, creating mouse models, and contributing to the understanding of epidermal diseases.
Section editors
Mef Nilbert: biomarkers and tumor genetics, molecularly targeted therapies, hereditary cancer syndromes, colorectal cancer, and sarcoma.
Mef Nilbert is a PhD in Tumor
Genetics and an MD with specialization in oncology. Her clinical responsibilities have been focused on medical oncology, oncogenetics, gastrointestinal cancer, and sarcoma. As a professor of Oncology, she has developed research groups at the Lund University in Sweden and at the Copenhagen University in Denmark. Her research field is at the intersection of genomics, epidemiology, and clinical management, with applicability for refined diagnostics, risk prediction, and implementation of molecularly targeted cancer therapies. Current projects relate to risk modeling, molecular taxonomy, epidemiologic patterns, and predictive markers for immunotherapy in Lynch syndrome.
She has led a regional cancer center in Sweden with responsibilities for cancer registration, clinical guidelines, and political initiatives to improve modern cancer care. As part of this work, she has more recently contributed to research related to disease patterns, multidisciplinary treatment, and patients' perspectives of cancer care.
Since 2017, she is the head of the Danish Cancer Society Research Center in Copenhagen, which is an international research environment with particular strengths in basic cancer biology and cancer epidemiology. The institute's scientific projects range from basic genomic repair to environmental risk factors and survivorship perspectives. As director of research, it is Prof. Nilbert's aim to further develop the institute's research agenda, grant high-quality studies, support training of cancer researchers of tomorrow, and stimulate cross-disciplinary scientific interaction and collaboration.
Professor Nilbert is also co-editor of Acta Oncologica that has a more epidemiological-clinical focus in cancer research. She is now looking forward to contributing to Molecular Oncology, in particular with regard to molecularly targeted therapies.
Klaus Pantel coordinates the European IMI consortium CANCER-ID (www.cancer-id.eu) on blood-based 'Liquid Biopsies' in lung and breast cancer, which comprises 37 partner institutions from academia, nonprofit organizations, and industry.
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